Stephanie DeArmey

Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants

Priya S. Kishnani, Paula Goldenberg, Stephanie DeArmey et al. · Molecular Genetics and Metabolism · 2009 · 379 citations

Medicine, Immunology, Pediatrics +5

Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial

Jordi Díaz‐Manera, Priya S. Kishnani, Hani Kushlaf et al. · The Lancet Neurology · 2021 · 184 citations · Full text

Veterinary Medicine, Internal Medicine, Pharmacotherapy +3

Case series: Odontohypophosphatasia or missed diagnosis of childhood/adult-onset hypophosphatasia? – Call for a long-term follow-up of premature loss of primary teeth

Mari Mori, Stephanie DeArmey, Thomas J. Weber et al. · Bone Reports · 2016 · 58 citations · Full text

Medicine, Oral Medicine, Oral Pathology +17

Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks

Priya S. Kishnani, Jordi Díaz‐Manera, António Toscano et al. · JAMA Neurology · 2023 · 55 citations · Full text

Life Sciences, Internal Medicine, Pharmacotherapy +8

Pulmonary outcome measures in long‐term survivors of infantile Pompe disease on enzyme replacement therapy: A case series

Mai K. ElMallah, Ankit K. Desai, Erica Nading et al. · Pediatric Pulmonology · 2020 · 15 citations · Full text

Medicine, Clinical Sciences, Pediatrics +12